Phase IV, single-center, randomized and open-label study to evaluate the impact of early treatment with a combination of an inhaled corticosteroid and a long-acting ß2 adrenergic agonist (budesonide / formoterol) versus standard of care on the evolution of the disease in vulnerable patients with COVID-19: INHALAVID TrialBy covidadmin | October 3, 2021 Read More
Treatment With Inhaled Corticosteroids in Patients Hospitalized Because of COVID19 PneumoniaBy covidadmin | October 3, 2021 Read More
Evolution of COVID-19 in Anticoagulated or Antiaggregated PatientsBy covidadmin | September 29, 2021 Read More
